Generation, characterization and preclinical studies of a human anti-L1CAM monoclonal antibody that cross-reacts with rodent L1CAM

Cited 10 time in scopus
Metadata Downloads

Full metadata record

DC FieldValueLanguage
dc.contributor.authorS Cho-
dc.contributor.authorI Park-
dc.contributor.authorJ Kim-
dc.contributor.authorM S Jeong-
dc.contributor.authorM Lim-
dc.contributor.authorE S Lee-
dc.contributor.authorJ H Kim-
dc.contributor.authorSemi Kim-
dc.contributor.authorH J Hong-
dc.date.accessioned2017-04-19T10:22:05Z-
dc.date.available2017-04-19T10:22:05Z-
dc.date.issued2016-
dc.identifier.issn19420862-
dc.identifier.uri10.1080/19420862.2015.1125067ko
dc.identifier.urihttps://oak.kribb.re.kr/handle/201005/13262-
dc.description.abstractL1 cell adhesion molecule (L1CAM) is aberrantly expressed in malignant tumors and plays important roles in tumor progression. Thus, L1CAM could serve as a therapeutic target and anti-L1CAM antibodies may have potential as anticancer agents. However, L1CAM is expressed in neural cells and the druggability of anti-L1AM antibody must be validated at the earliest stages of preclinical study. Here, we generated a human monoclonal antibody that is cross-reactive with mouse L1CAM and evaluated its pharmacokinetic properties and anti-tumor efficacy in rodent models. First, we selected an antibody (Ab4) that binds human and mouse L1CAM from the human naive Fab library using phage display, then increased its affinity 45-fold through mutation of 3 residues in the complementarity-determining regions (CDRs) to generate Ab4M. Next, the affinity of Ab4M was increased 1.8-fold by yeast display of single-chain variable fragment containing randomly mutated light chain CDR3 to generate Ab417. The affinities (KD) of Ab417 for human and mouse L1CAM were 0.24 nM and 79.16 pM, respectively. Ab417 specifically bound the Ig5 domain of L1CAM and did not exhibit off-target activity, but bound to the peripheral nerves embedded in normal human tissues as expected in immunohistochemical analysis. In a pharmacokinetics study, the mean half-life of Ab417 was 114.49 h when a single dose (10 mg/kg) was intravenously injected into SD rats. Ab417 significantly inhibited tumor growth in a human cholangiocarcinoma xenograft nude mouse model and did not induce any adverse effect in in vivo studies. Thus, Ab417 may have potential as an anticancer agent.-
dc.publisherT&F (Taylor & Francis)-
dc.titleGeneration, characterization and preclinical studies of a human anti-L1CAM monoclonal antibody that cross-reacts with rodent L1CAM-
dc.title.alternativeGeneration, characterization and preclinical studies of a human anti-L1CAM monoclonal antibody that cross-reacts with rodent L1CAM-
dc.typeArticle-
dc.citation.titleMabs-
dc.citation.number2-
dc.citation.endPage425-
dc.citation.startPage414-
dc.citation.volume8-
dc.contributor.affiliatedAuthorSemi Kim-
dc.contributor.alternativeName조슬기-
dc.contributor.alternativeName박인수-
dc.contributor.alternativeName김해정-
dc.contributor.alternativeName정문식-
dc.contributor.alternativeName임문예-
dc.contributor.alternativeName이응숙-
dc.contributor.alternativeName김진홍-
dc.contributor.alternativeName김세미-
dc.contributor.alternativeName홍효정-
dc.identifier.bibliographicCitationMabs, vol. 8, no. 2, pp. 414-425-
dc.identifier.doi10.1080/19420862.2015.1125067-
dc.subject.keywordAffinity maturation-
dc.subject.keywordCancer-
dc.subject.keywordHuman monoclonal antibody-
dc.subject.keywordL1CAM-
dc.subject.keywordPhage display-
dc.subject.keywordYeast display-
dc.subject.localAffinity maturation-
dc.subject.localCancer-
dc.subject.localHuman monoclonal antibody-
dc.subject.localL1CAM-
dc.subject.localPhage display-
dc.subject.localYeast display-
dc.description.journalClassY-
Appears in Collections:
Division of Biomedical Research > Immunotherapy Research Center > 1. Journal Articles
Files in This Item:
  • There are no files associated with this item.


Items in OpenAccess@KRIBB are protected by copyright, with all rights reserved, unless otherwise indicated.